期刊文献+

水痘减毒活疫苗无明胶稳定剂的筛选和应用 被引量:3

Screening and application of gelatin-free stabilizer for live attenuated varicella vaccine
原文传递
导出
摘要 目的 研制不含明胶的新型稳定剂,以提高水痘减毒活疫苗的安全性.方法 以现行水痘减毒活疫苗稳定剂配方为基础,去除明胶,配制4种不同的新型稳定剂(B、C、D、E配方).用无明胶稳定剂制备水痘减毒活疫苗,并将制备的无明胶稳定剂疫苗(B、C、D、E疫苗)与现行的含明胶稳定剂疫苗(作为对照的A疫苗)进行比较,确定最佳稳定剂配方.结果 疫苗成品于37℃放置7d后,A、B、C、D、E疫苗的相关质量指标均符合《水痘减毒活疫苗注册标准》的要求,病毒滴度分别为3.6、3.5、3.3、3.3、3.3 lgPFU/0.5 ml,但C、D、E疫苗的病毒滴度已降至临界值.疫苗成品于2~8℃放置24个月后,A、B、C、D、E疫苗的病毒滴度分别为3.4、3.4、3.2、3.0、2.8 lgPFU/0.5 ml,其中C、D、E疫苗的病毒滴度已低于规定的标准(3.3 lgPFU/0.5 ml),仅B疫苗的相关质量标准符合规定的要求,且与A疫苗(对照)没有差异.结论 去除明胶的B配方稳定剂对水痘病毒有较好的保护作用. Objective To develope new gelatin-free stabilizers in order to improve the safety of live attenuated varicella vaccine,Methods Based on the current stabilizer formula of live attenuated varicella vaccine,four new stabilizers (B,C,D,E formulas) were formulated by removing gelatin.Vaccines without gelatin (B,C,D,E vaccines) were prepared with the formulated gelatin-free stabilizers and compared with the current live attenuated varicella vaccine with gelatin (A vaccine as control).The optimized stabilizer formula was determined.Results After 7 days at 37 ℃,the relevant qualities of all vaccines conformed with the requirement of Registration Criteria of Live Attenuated Vaccine Varicella,and the virus titers of A,B,C,D,E vaccines were 3.6,3.5,3.3,3.3 and 3.3 lgPFU/0.5 ml,respectively,but the virus titers of C,D,E vaccines have dropped to critical value.After 24 months at 2-8 ℃,the virus titers of A,B,C,D,E vaccines were 3.4,3.4,3.2,3.0 and 2.8 lgPFU/0.5 ml,respectively.Among the four vaccines without gelatin,the virus titers of C,D,E vaccines have been below the requirement (3.3 lgPFU/0.5 ml),only B vaccine met the requirement and was the same as A vaccine.Conclusion The B formula stabilizer without gelatin has better protection for varicella virus.
出处 《国际生物制品学杂志》 CAS 2014年第6期261-264,共4页 International Journal of Biologicals
基金 2011上海市引进技术的吸收与创新年度计划
关键词 水痘减毒活疫苗 辅药 稳定性 Chickenpox vaccine Excipients Stability
  • 相关文献

参考文献7

二级参考文献68

  • 1庞成华,彭佩霞,刘小琳,王桂秋,陈秀珍,王用楫.北京株水痘活疫苗的研制[J].中国生物制品学杂志,1994,7(4):156-158. 被引量:6
  • 2李群,袁勤生.海藻糖的性质及应用[J].中国生化药物杂志,1995,16(5):231-233. 被引量:14
  • 3陈志慧,王宪明,殷月娣,王亮,沈谊清,徐建军,吕国贞,王树巧.水痘减毒活疫苗的研制及免疫效果观察[J].国际生物制品学杂志,2006,29(3):97-100. 被引量:30
  • 4石少辉(译).美国儿童接种二次水痘疫苗[J].英国医学杂志中文版,2007,10(4):215-215. 被引量:1
  • 5张延龄,张晖,戴科.疫苗学[M].北京:科学出版社,2006.
  • 6OZAKI T,NISHIMURA N, MUTO T,et al. Safety and immuno- genicity of gelatin-free varicella vaccine in epidemiological and serological studies in Japan [ J ]. Vaccine, 2005, 23 ( 10 ) : 1205 - 1208.
  • 7长春百克生物科技有限公司.一种不含明胶的疫苗冻干保护剂:中国,CN101537186A[P].2009-09-23.
  • 8BOOT HJ, DE MELKER HE, STOLK EA, et al. Assessing the introduction of universal varicella vaccination in the Netherlands [J]. Vaccine, 2006, 24(37 -39): 6288 -6299.
  • 9Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices. Update:recommendations from the advisory committee on immunization practices (ACIP) regarding administration of combination MMRV vaccine [ R ]. MMWR Mor Mortal Wkly Rep , 2008, 57(10):258-260.
  • 10OXMAN MN, MD, LEVIN MJ, et al. A Vaccine to prevent her- pes zoster and postherpetic neuralgia in older adults[ J]. N Eng J Med, 2005, 352(20) :2271 -2284.

共引文献39

同被引文献20

  • 1TATE J E, BURTON H, BOSCHI-PINTO C, et al. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years betbre the introduction of universal rota- virus vaccination programmes analysis [J]. Lancet Infect Dis a systematic review and recta- 2012, 12 (2): 136-141.
  • 2KANG M S, JANG H, KIM M C, et al. Development of a stabilizer for lyophilization of an attenuated duck viral hepatitis vaccine [J]. Pouh Sci, 2010, 89 (6): 1167-1170.
  • 3REYNOLDS B, IZARD R S. Vaccine stabilizer method: US Patent 20, 050, 186, 22l [P]. 2005-8-25.
  • 4REYNOLDS B, IZARD R S. Vaccine stabilizer and method of use: US Patent 20, 030, 215, 455 [P]. 2003-11-20.
  • 5CLARK H F, BURKE C J, VOLKIN D B, et aL Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavinis vaccine in a new stabilizer/buffer liquid formulation [J]. Pediatric Infect Dis J, 2003, 22 (10): 914-920.
  • 6LEIGH S A, BRANTON S L, COLLIER S D. Stabilization of live Mycoplasma gallisept,:cum vaccines during vaccination with second-generation Spray-Vac vaccine stabilizer [J]. J Appl Poultry Res, 2008, 17 (2): 278-282.
  • 7DHERE R M, PISAL S S, ZADE J K. Stable, dried rotavirus vaccine, compositions and process for preparation thereof: US Patent 8, 795, 686 [P]. 2014-08-05.
  • 8PULLIAM B L. Rotavints preparations with excess calcium ions and high viscosities that ensure viability at elevated temeratures: US Patent 20, 140, 356, 396 [P]. 2014-12-04.
  • 9SUN T, LEVESQUE P M, BROWN A T, et al. Vaccine stabilizer: US Patent Application 13/355, 158 [P]. 2012-01- 20.
  • 10段凯,李黎.冻干乙型脑炎减毒活疫苗非动物源性稳定剂的配方及其缓冲液的筛选[J].中国生物制品学杂志,2012,25(11):1431-1433. 被引量:5

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部